Epirubicin+Cyclophosphamide

DRUG3 trials

Sponsors

Tao OUYANG, TTY Biopharm, The First Affiliated Hospital with Nanjing Medical University

Conditions

Breast CancerTNBC - Triple-Negative Breast Cancer

Phase 2

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

TTY BiopharmBreast Cancer

Start: 2010-06-30End: 2022-10-31Target: 254Updated: 2021-11-23

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

RecruitingNCT05834582

The First Affiliated Hospital with Nanjing Medical UniversityTNBC - Triple-Negative Breast Cancer

Start: 2023-04-08End: 2026-06-01Target: 60Updated: 2023-04-28

Phase 4

Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

CompletedNCT01199432

Tao OUYANGBreast Cancer

Start: 2010-10-31End: 2014-12-31Target: 501Updated: 2015-06-10